Journal Image
Current Angiogenesis
ISSN (Print): 2211-5528
ISSN (Online): 2211-5536
Epub Full Text Article
DOI: 10.2174/2211552802666140704164740      Price:  $95

Anti-Angiogenesis in the Treatment of Genito-Urinary Cancers: Last Updates

Author(s): El Karak Fadi, Kourie Hampig Raphael, Chebib Ralph, Tabchi Samer, Daher Alain, Kattan Joseph and Ghosn Marwan
Angiogenesis is a common mechanism in tumor growth. In the era of targeted therapy, inhibiting this mechanism by anti-angiogenic drugs revealed many positive results in different cancers. The urological cancers (Prostate, Bladder, Testis and Kidney) represent approximately 25% of all diagnosed cancers in both sexes.

Anti-angiogenic drugs are the cornerstone of therapy in Renal Cell Carcinoma and have shown somewhat promising results in prostate cancer. However, studies in urothelial carcinoma of the bladder have been disappointing and catastrophic in germ cell tumors.

In this paper, we reported the majority of trials evaluating the anti-angiogenic drugs in urological cancers.

Hematology-Oncology Department, Saint Joseph University, Faculty of Medicine, Beirut, Lebanon